citrulline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
3103 372-75-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • citrulline
  • L-Citrulline
  • sigma-Ureidonorvaline
  • Molecular weight: 175.19
  • Formula: C6H13N3O3
  • CLOGP: -3.36
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 4
  • TPSA: 118.44
  • ALOGS: -0.90
  • ROTB: 5

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -2.068 Moderate 0.75
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.668 Moderate 0.75
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 6.012 10^-6 cm/s Moderate 0.75
dh-clint Dog hepatocyte intrinsic clearance 0.738 uL/min/10^6 cells Moderate 0.75
dppb Dog plasma protein binding (% unbound) 86.430 % Moderate 0.75
fcs-ppb Fetal calf serum protein binding (% unbound) 64.750 % Moderate 0.75
herg hERG pIC50 5.281 pIC50 Moderate 0.75
hh-clint Human hepatocyte intrinsic clearance 2.223 uL/min/10^6 cells Moderate 0.75
hlm-clint Human liver microsomal intrinsic clearance 5.297 uL/min/mg protein Moderate 0.75
hppb Human plasma protein binding (% unbound) 82.950 % Moderate 0.75
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK1,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1 39
kinase-selectivity-class ACVR2B,AXL,BMX,BRAF,CAMK2D,CDK9,DDR1,EIF2AK3,EPHB4,GRK2,MAP2K6,MAP3K14,MAP3K21,MAPK7,PIK3CD,SIK2,STK33,TEK,TGFBR1 19
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.208 Moderate 0.75
mh-clint Mouse hepatocyte intrinsic clearance 0.883 Moderate 0.75
mppb Mouse plasma protein binding (% unbound) 95.710 Moderate 0.75
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.766 Moderate 0.75
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 88.040 % Moderate 0.75
rh-clint Rat hepatocyte intrinsic clearance 3.556 uL/min/10^6 cells Moderate 0.75
rh-fuinc Rat hepatocyte fraction unbound in incubation 88.040 % Moderate 0.75
rppb Rat plasma protein binding (% unbound) 92.960 % Moderate 0.75
solubility-dd Solubility at pH 7.4 in DMSO 704.693 uM Moderate 0.75

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 83.54 42.52 8 135 48 90628256
Hyperammonaemia 52.33 42.52 9 134 6466 90621838
Ammonia increased 47.63 42.52 8 135 4978 90623326

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 64.67 47.94 7 166 56 42621106

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemic crisis 131.32 33.54 14 387 108 110588790
Hyperammonaemia 59.60 33.54 13 388 13719 110575179
Ammonia increased 54.16 33.54 11 390 8239 110580659

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
CHEBI has role CHEBI:27027 micronutrient
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:35674 antihypertensive agent
CHEBI has role CHEBI:50267 protective agent
CHEBI has role CHEBI:50733 nutraceutical
CHEBI has role CHEBI:61908 EC 1.14.13.39 (nitric oxide synthase) inhibitor
CHEBI has role CHEBI:65023 anti-asthmatic agent
CHEBI has role CHEBI:75771 mouse metabolite
CHEBI has role CHEBI:75772 <em>Saccharomyces cerevisiae </em> metabolite
CHEBI has role CHEBI:75835 anti-anaemic agent
CHEBI has role CHEBI:76971 <em>Escherichia coli</em> metabolite
CHEBI has role CHEBI:77746 human metabolite
CHEBI has role CHEBI:176497 geroprotector
CHEBI has role CHEBI:59174 hapten
CHEBI has role CHEBI:83056 <em>Daphnia magna</em> metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hyperammonemia off-label use 9360008
Arginase deficiency off-label use 23501004 DOID:9278
Congenital hyperammonemia, type I off-label use 62522004
Ornithine Carbamyltransferase Deficiency off-label use 80908008 DOID:9271
Lysinuric protein intolerance off-label use 303852004 DOID:0060439
Arginosuccinate Lyase Deficiency off-label use




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.12 acidic
pKa2 11.32 acidic
pKa3 13.72 acidic
pKa4 9.52 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4025081 VUID
N0000171745 NUI
D07706 KEGG_DRUG
4025081 VANDF
C0008864 UMLSCUI
CHEBI:16349 CHEBI
CIR PDB_CHEM_ID
CHEMBL444814 ChEMBL_ID
DB00155 DRUGBANK_ID
D002956 MESH_DESCRIPTOR_UI
9750 PUBCHEM_CID
29VT07BGDA UNII
2567 RXNORM
175680 MMSL
22711 MMSL
NOCODE MMSL
d06051 MMSL
004479 NDDF
30022007 SNOMEDCT_US
441997001 SNOMEDCT_US
722 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lipovite HUMAN PRESCRIPTION DRUG LABEL 13 70104-128 INJECTION 1 mg INTRAMUSCULAR unapproved drug other 1 sections